10-Q: Sage Therapeutics Reports Reduced Losses and Revenue Growth Amidst Pending Supernus Acquisition and Pipeline Restructuring

Sage Therapeutics announced a significant reduction in net losses and substantial revenue growth for the second quarter and first half of 2025, driven by ZURZUVAE commercialization, while navigating a pending acquisition by Supernus Pharmaceuticals and ongoing legal challenges.

Summary

• Net loss for the three months ended June 30, 2025, significantly decreased to $49.7 million from $102.9 million in the same period of 2024.
• Net loss for the six months ended June 30, 2025, decreased to $111.9 million from $211.3 million in the same period of 2024.
• Total revenues for the three months ended June 30, 2025, increased to $31.7 million from $8.7 million in the same period of 2024.
• Total revenues for the six months ended June 30, 2025, increased to $45.7 million from $16.6 million in the same period of 2024.
• Collaboration revenue from Biogen's ZURZUVAE sales in the U.S. increased to $23.2 million for Q2 2025 and $37.0 million for H1 2025, up from $7.4 million and $13.6 million respectively in 2024.
• Over 4,000 ZURZUVAE prescriptions were shipped in Q2 2025, a 36% increase from the prior quarter, with over 13,500 total prescriptions shipped since commercial launch through Q2 2025.
• Research and development expenses decreased by $38.6 million for Q2 2025 and $87.6 million for H1 2025, primarily due to the 2024 Restructuring and discontinuation of SAGE-324 and dalzanemdor programs.
• Selling, general and administrative expenses increased by $6.0 million for Q2 2025 and $11.0 million for H1 2025, driven by higher professional fees related to strategic alternatives review and litigation, and increased commercialization efforts for ZURZUVAE.
• Cash, cash equivalents, and marketable securities totaled $365.6 million as of June 30, 2025, down from $504.4 million at December 31, 2024.
• The company had an accumulated deficit of $3.1 billion as of June 30, 2025.
• The company entered into a Merger Agreement with Supernus Pharmaceuticals, Inc. on June 13, 2025, for $8.50 per share in cash plus a Contingent Value Right (CVR) of up to $3.50 per share.
• The tender offer for the Supernus acquisition commenced on July 2, 2025, with an initial expiration date of July 30, 2025.
• The company discontinued commercial availability of ZULRESSO as of December 31, 2024, and withdrew its NDA in April 2025.
• Development of dalzanemdor was discontinued in November 2024 following failed Phase 2 studies.
• Biogen terminated its collaboration agreement solely with respect to SAGE-324 on a worldwide basis, effective February 17, 2025, after the Phase 2b KINETIC 2 Study failed to meet its primary endpoint.
• The company is evaluating other potential indications for SAGE-324, including seizures in developmental and epileptic encephalopathies (DEEs), with an update expected mid-2025.
• Data from a Phase 1 multiple ascending dose study of SAGE-319 is expected by late 2025.
• The company is cooperating with an SEC subpoena regarding its NDA for zuranolone for MDD and related communications.
• Multiple securities class action and derivative lawsuits have been filed against the company and its current/former officers/directors, including two related to the Merger Agreement.

Sentiment

Score: 4

Explanation: While the company showed significant improvement in reducing net losses and growing revenue, it continues to operate at a substantial loss with a large accumulated deficit and declining cash reserves. The pending acquisition introduces uncertainty, and the discontinuation of multiple pipeline programs (SAGE-324, dalzanemdor) highlights ongoing R&D challenges. Legal proceedings also add a layer of risk.

Positives

• Net loss significantly reduced for both the three and six months ended June 30, 2025, compared to the prior year periods, indicating improved financial performance.
• Total revenues increased substantially, driven by a significant rise in collaboration revenue from Biogen's ZURZUVAE sales.
• ZURZUVAE prescription shipments increased by 36% quarter-over-quarter, demonstrating growing market adoption for postpartum depression treatment.
• Anticipated cost savings from the October 2024 corporate reorganization and pipeline prioritization are expected to reduce operating expenses in 2025.
• Payor coverage for ZURZUVAE is in place for a majority of commercial and Medicaid covered lives with minimal restrictions, including all three national Pharmacy Benefit Managers.

Negatives

• The company continues to incur significant net losses and has an accumulated deficit of $3.1 billion, indicating ongoing unprofitability.
• Cash, cash equivalents, and marketable securities decreased by $138.8 million from December 31, 2024, to June 30, 2025, reflecting continued cash burn from operations.
• The collaboration with Biogen for SAGE-324 products was terminated, and development of dalzanemdor was discontinued, representing setbacks in the pipeline.
• The company faces multiple ongoing legal proceedings, including securities class actions, derivative litigations, and an SEC investigation, which could result in substantial costs and management distraction.
• The proposed acquisition by Supernus Pharmaceuticals introduces uncertainty and potential risks, including a termination fee of $22.4 million if the merger agreement is terminated under specified circumstances.

Risks

• The proposed acquisition by Supernus Pharmaceuticals, Inc. may not be completed within the anticipated timeframe or at all, which could adversely affect business, financial results, and operations.
• Failure to successfully commercialize ZURZUVAE for postpartum depression (PPD) in the U.S. could limit revenue generation, due to factors like market acceptance, payor coverage restrictions, or competition.
• The rejection of Biogen's unsolicited acquisition proposal and enforcement of the stock purchase agreement terms may adversely impact the relationship with Biogen, potentially affecting ZURZUVAE sales.
• Future business prospects heavily depend on the ability to successfully develop and gain regulatory approval for product candidates, which is a long, expensive, and uncertain process with high failure rates.
• If the target patient populations for products and product candidates are smaller than anticipated, or market assumptions are incorrect, profitability could be materially adversely impacted.
• Undesirable side effects or safety issues identified during the use of marketed products or product candidates could adversely affect market acceptance, delay regulatory approval, or result in significant negative consequences like boxed warnings or REMS.
• Failure to achieve positive results in clinical trials and non-clinical studies of product candidates could prevent further development or regulatory approval.
• Inability to generate expected revenues from existing products or achieve cash milestone payments from collaboration partners, coupled with higher-than-expected expenses, could lead to insufficient cash to fund future operations.
• Impairment of third-party suppliers' ability to provide product or meet regulatory standards could negatively impact the ability to achieve goals and plans.
• Competing therapies, including lower-cost antidepressants for PPD, could adversely affect revenue from ZURZUVAE or other product candidates.
• Existing or future collaborations may not lead to successful development or commercialization, and disagreements or failures by collaborators could adversely affect the business.
• Inability to adequately protect proprietary technology or obtain and maintain issued patents could allow competitors to compete more directly.
• Loss of rights to certain licensed intellectual property or inability to obtain future licenses could prevent continued development or commercialization of products.
• Existing or future laws, regulations, executive orders, or policies aimed at reducing healthcare costs, including drug pricing and reimbursement reforms, may materially adversely affect business or results of operations.
• Non-compliance with healthcare laws and regulations could expose the company to criminal sanctions, civil penalties, contractual damages, and reputational harm.
• The stock price may fluctuate significantly due to various factors, including clinical trial results, regulatory decisions, competition, and macroeconomic conditions.
• Inadequate funding for regulatory agencies (FDA, SEC) or other government disruptions could hinder their ability to perform normal business functions, impacting the company's operations.
• Employees, contractors, or collaborators engaging in misconduct, including non-compliance with regulatory standards or insider trading, could lead to significant liability and reputational harm.
• Changes in U.S. patent law, including the America Invents Act and Supreme Court rulings, could diminish the value of patents and impair the ability to protect products.
• The CREATES Act exposes the company to possible litigation and damages by competitors claiming insufficient product supply for testing, potentially facilitating earlier generic competition.

Future Outlook

The company anticipates that existing cash, cash equivalents, and marketable securities, along with anticipated funding from ongoing collaborations and estimated revenues (excluding potential milestone payments), will support operations to mid-2027. Operating expenses are expected to decrease in 2025 compared to 2024 due to pipeline prioritization and cost savings from the 2024 Restructuring, but significant operating expenses will continue, particularly for ZURZUVAE commercialization and advancing product candidates. The company expects to incur significant expenses and operating losses for the foreseeable future and will require additional financing to fund future operations.

Management Comments

• Our mission is to pioneer solutions to deliver life-changing brain health medicines, so every person can thrive.
• We are focused on the ongoing launch of ZURZUVAE for the treatment of women with PPD and our prioritized pipeline development efforts.
• Additional sales force resources are expected to help accelerate demand for ZURZUVAE for the treatment of women with PPD.
• Our current commercialization investment plan includes digital marketing campaigns to help expand market growth in PPD, along with increased disease state awareness efforts to support improved PPD screening and diagnosis.

Industry Context

The biopharmaceutical industry is highly competitive, with numerous companies, universities, and research organizations developing similar products. Competition focuses on efficacy, safety, convenience, availability, and price. The industry is also subject to extensive litigation regarding intellectual property and evolving healthcare regulations aimed at reducing costs, such as the ACA and IRA, which can impact drug pricing and reimbursement. The market for CNS disorders, including PPD, is a key area of focus, with existing therapies like SSRIs/SNRIs and new entrants in the neuroactive steroid space.

Comparison to Industry Standards

• ZURZUVAE is the first oral, once-daily, 14-day treatment specifically indicated for adults with PPD, differentiating it from the previous intravenous ZULRESSO and other PPD treatments.
• LPCN 1154 (Lipocine, Inc.), an oral formulation of brexanolone, is in Phase 3 clinical trials for PPD, representing a direct competitor to ZURZUVAE's mechanism of action.
• NORA520 (DuKang Pharmaceuticals, Inc.) is in Phase 2 clinical trials for severe PPD.
• BRII-296 (Brii Biosciences), an intramuscular formulation of brexanolone, is under development for PPD.
• Other companies with product candidates in Phase 2 clinical trials for PPD include Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (HS-10353), GH Research PLC (GH001), and Reunion Neuroscience, Inc. (RE104).
• In the neuroactive steroid field, Marinus Pharmaceuticals, Inc. (acquired by Immedica Pharma AB) has FDA-approved ganaxolone for CDKL5 deficiency disorder, and Cerevel Therapeutics, Inc. (acquired by AbbVie Inc.) is developing darigabat for epilepsy and panic disorder, indicating a competitive landscape for GABA A modulators.

Corporate Governance

Legal Proceedings

• A federal securities class action lawsuit (Korver v. Sage Therapeutics, Inc., et al.) was filed on August 28, 2024, alleging violations of U.S. securities laws (Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5) for stock purchases between April 12, 2021, and July 23, 2024, seeking unspecified damages. An amended complaint was filed on March 3, 2025, and a motion to dismiss was filed on April 17, 2025.
• The company received a subpoena from the SEC Enforcement Division on October 16, 2024, requesting documents and information related to the zuranolone MDD NDA, including communications with the FDA and any containing material nonpublic information. The company is cooperating.
• Three shareholder derivative litigations (Zhu Derivative Litigation, Matton Derivative Litigation, Pizzelanti Derivative Litigation) were commenced in the Southern District of New York in March, May, and May 2025, respectively, purportedly on behalf of the company against current and former officers and directors. These allege violations of Section 14(a) of the Exchange Act and Rule 14a-9, breaches of fiduciary duty, unjust enrichment, and waste of corporate assets, seeking unspecified damages and equitable relief. These have been submitted for consolidation.
• Two complaints (Taylor v. Sage Therapeutics, Inc., et al. and Morgan v. Sage Therapeutics, Inc., et al.) were filed in New York state court on July 8 and July 9, 2025, respectively, by purported stockholders relating to the Merger Agreement. These allege negligent misrepresentation, concealment, and negligence, claiming the Schedule 14D-9 omitted material information, and seek an injunction against the merger or damages if consummated.

Related Party Transactions

• The company has a collaboration agreement with Biogen MA Inc. and Biogen International GmbH (together, Biogen) for the co-development and co-commercialization of SAGE-217 products (including ZURZUVAE) in the U.S. and exclusive rights for Biogen in other territories. The company and Biogen share equally in U.S. operating profits and losses.
• Biogen is a related party due to its purchase of 6,241,473 shares of the company's common stock for $650.0 million in December 2020.
• The company recognized $23.2 million and $37.0 million in collaboration revenue related party for its share of Biogen's net ZURZUVAE sales to customers in the U.S. for the three and six months ended June 30, 2025, respectively.
• The company recorded net reimbursements to Biogen of $3.0 million and $2.7 million for research and development expenses for the three and six months ended June 30, 2025, respectively, and $6.2 million and $11.0 million for selling, general and administrative expenses for the same periods, due to Biogen incurring a greater share of these costs.
• A collaboration receivable related party of $16.3 million was recorded as of June 30, 2025, representing net reimbursement due from Biogen.

Stakeholder Impact

• Shareholders: Potential for a fixed cash payout ($8.50/share) and contingent value rights (up to $3.50/share) from the Supernus acquisition, but also face dilution from potential future capital raises and stock price volatility due to ongoing losses and legal issues.
• Employees: Impacted by the October 2024 restructuring, which included a reduction of approximately 33% of the total workforce and 55% of the R&D workforce, leading to uncertainty about roles during the pending acquisition.
• Customers (Patients): ZURZUVAE's commercial availability for PPD offers a new oral treatment option, with patient support programs and increasing payor coverage aiming to improve access. Discontinuation of ZULRESSO removes an older treatment option.
• Suppliers/Vendors: Reliance on third-party suppliers for manufacturing creates dependency and potential risks if suppliers fail to meet standards or face disruptions.
• Creditors: Continued net losses and cash burn indicate ongoing financial challenges, though the company projects sufficient cash to mid-2027, additional financing will be required.

Next Steps

• Completion of the tender offer and merger with Supernus Pharmaceuticals, Inc. by July 30, 2025, unless extended.
• Continued commercialization of ZURZUVAE for the treatment of women with PPD in the U.S., including ongoing engagement with payors and digital marketing campaigns.
• Evaluation of next steps for SAGE-324, including potential indications like seizures in developmental and epileptic encephalopathies (DEEs), with an update expected mid-2025.
• Announcement of data from a Phase 1 multiple ascending dose study of SAGE-319 by late 2025, followed by evaluation of next steps.
• Continued exploration of targeted work within the NMDA receptor negative allosteric modulator platform with SAGE-817 and SAGE-039.
• Ongoing cooperation with the SEC investigation and defense against multiple securities class action and derivative lawsuits.

Key Dates

Recommendation

The company is subject to a pending acquisition by Supernus Pharmaceuticals, Inc. via a tender offer at $8.50 cash per share plus contingent value rights (CVRs) of up to $3.50 per share. Given the high probability of the merger's completion, the stock price is likely to trade close to the cash offer price, factoring in any discount for the CVRs' uncertainty and merger completion risk. For investors, holding shares to tender them in the offer or selling them in the market to avoid CVR uncertainty are the primary considerations, rather than a fundamental 'buy' or 'sell' based on the company's standalone operational performance. The operational improvements (reduced losses, revenue growth) are positive, but the long-term standalone viability is overshadowed by the acquisition.

Keywords

Biopharmaceutical, Brain Health, Postpartum Depression, PPD, ZURZUVAE, Zuranolone, Neuroactive Steroid, GABA A Receptor, Neuropsychiatry, Neurodevelopmental Disorders, Supernus Acquisition, SEC Filing, Clinical Trials, Drug Development, Commercialization, Biogen Collaboration, Shionogi Collaboration, SAGE-319, SAGE-324, Dalzanemdor, NMDA Receptor, Financial Results, Cash Flow, Restructuring, Legal Proceedings, Intellectual Property, Regulatory Approval, Healthcare Policy